Company Filing History:
4 out of 505 
2 out of 25 
Years Active: 2021-2025
Title: Innovations by Jeffrey Tyner in Acute Myeloid Leukemia Treatment
Introduction
Jeffrey Tyner is a notable inventor based in Portland, OR, who has made significant contributions to the field of cancer treatment, particularly in acute myeloid leukemia (AML). With a total of three patents to his name, Tyner's work focuses on innovative methods for treating mutations associated with this aggressive form of leukemia.
Latest Patents
Tyner's latest patents include groundbreaking methods for treating Acute Myeloid Leukemia in the presence of gene mutations. His first patent outlines useful methods for treating AML in humans, specifically targeting the genetic mutations that complicate treatment. Another significant patent involves diagnostic methods for identifying cancer-bearing subjects who are suitable for treatment with CPX-351. This includes genetic and ex vivo testing of cells from candidates. Additionally, his research indicates that combination treatment with CPX-351 and FLT-3 inhibitors can enhance the uptake and reduce toxicity of CPX-351.
Career Highlights
Throughout his career, Jeffrey Tyner has worked with prominent institutions such as Oregon Health & Science University and Celator Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer treatment.
Collaborations
Tyner has collaborated with esteemed colleagues, including Max Gordon and Paul Tardi. These partnerships have contributed to the advancement of his research and the successful development of